本文關(guān)鍵詞：胃復(fù)方對胃癌SGC-7901細(xì)胞株增殖及PPARγ基因活性的影響　出處：《湖南中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 胃復(fù)方 含藥血漿 胃癌SGC-7901細(xì)胞株 PPARγ

【摘要】：目的:通過觀察胃復(fù)方含藥血漿對胃癌SGC-7901細(xì)胞株增殖及對PPARγ(過氧化物酶增殖激活受體γ)的影響,對胃復(fù)方含藥血漿影響胃癌細(xì)胞增殖可能機(jī)制進(jìn)行探討。方法:以胃復(fù)方含藥血漿(終濃度為10%)空白組、低劑量組、中劑量組、高劑量組作用于胃復(fù)方SGC-7901細(xì)胞株,24h、48h、72h后分別用CCK-8法檢測增殖抑制率。不同濃度的胃復(fù)方含藥血漿作用胃癌SGC-7901細(xì)胞株后48h,以熒光定量法(q PCR)檢測PPARγ在胃癌SGC-7901細(xì)胞株中的表達(dá)。結(jié)果:低劑量胃復(fù)方含藥血漿的IC_(50)為11.1%±2.0%,中劑量胃復(fù)方含藥血漿的IC_(50)為13.5%±3.1%,高劑量胃復(fù)方含藥血漿IC_(50)為12.3%±1.5%。各含藥血漿IC_(50)比較差異均無顯著意義(p0.05)。由此確定在研究各劑量含藥血漿在對SGC-7901細(xì)胞株增殖影響時(shí),各含藥血漿的加入濃度均取10%。胃復(fù)方含藥血漿能抑制SGC-7901細(xì)胞增殖,作用胃癌SGC-7901細(xì)胞株24小時(shí)后,胃復(fù)方空白組、低劑量組、中劑量組、高劑量組OD值分別為0.697±0.040、0.654±0.032、0.548±0.048、0.036±0.029;48小時(shí)后OD值分別為1.233±0.081、1.131±0.040、0.856±0.055、0.413±0.065;72小時(shí)后OD值分別為1.736±0.026、1.362±0.013、0.748±0.024、0.326±0.020,差異均有統(tǒng)計(jì)學(xué)意義(p0.05)。胃復(fù)方含藥血漿在作用胃癌SGC-7901細(xì)胞48小時(shí)后,PPARγ基因隨著濃度的增高表達(dá)上調(diào),低劑量、中劑量、高劑量胃復(fù)方含藥血漿的相對表達(dá)量分別是空白血漿的(41.1172±1.9615)倍、(4448.5509±4.7522)倍、(14893.2846±1.0381)倍,與空白組相比差異有統(tǒng)計(jì)學(xué)意義(p0.05)。結(jié)論:1、胃復(fù)方含藥血漿隨藥物濃度的增加和作用時(shí)間的延長對胃癌SGC-7901細(xì)胞的增殖抑制作用逐漸增加,呈時(shí)間和濃度依賴性。提示胃復(fù)方對胃癌增殖有抑制作用。2、胃復(fù)方含藥血漿干預(yù)后,SGC-7901細(xì)胞PPARγ表達(dá)水平呈劑量依賴性增加,提示胃復(fù)方含藥血漿可能通過上調(diào)PPARγ基因表達(dá)的途徑來抑制胃癌SGC-7901細(xì)胞增殖。
[Abstract]:Objective: to observe the effect of gastric compound drug containing plasma on proliferation of gastric cancer SGC-7901 cell line and on PPAR 緯 (peroxidase proliferation-activated receptor 緯). To explore the possible mechanism of the effect of gastric compound plasma containing drugs on the proliferation of gastric cancer cells. Methods: blank group, low dose group and middle dose group were used in gastric compound plasma containing medicine (final concentration was 10). The high dose group was treated with gastric compound SGC-7901 cell line for 24 h and 48 h. After 72 hours, the inhibition rate of proliferation was detected by CCK-8 assay. 48 hours after different concentrations of compound plasma were treated with gastric cancer SGC-7901 cell line. The expression of PPAR 緯 in gastric cancer SGC-7901 cell line was detected by fluorescence quantitative assay. Results: the low dose gastric compound plasma ICSP 50 was used to detect the expression of PPAR 緯 in gastric cancer SGC-7901 cell line. It was 11.1% 鹵2.0%. The ICSP 50 of medium dose gastric compound plasma was 13.5% 鹵3.1%. The plasma ICS 50 of high dose gastric compound was 12.3% 鹵1.5.There was no significant difference between the two groups (P 0.05). It was determined that the effects of different doses of plasma containing drugs on the proliferation of SGC-7901 cell line were studied. The concentration of each drug plasma was 10. The gastric compound plasma could inhibit the proliferation of SGC-7901 cells. 24 hours after the action of gastric cancer SGC-7901 cell line, the stomach compound blank group. The OD values of low dose group, middle dose group and high dose group were 0.697 鹵0.040 ~ 0.654 鹵0.032 ~ 0.548 鹵0.048 鹵0.048 鹵0.036 鹵0.029 respectively. After 48 hours, the OD values were 1.233 鹵0.081, 1.131 鹵0.040, 0.856 鹵0.055, 0.413 鹵0.065, respectively. After 72 hours, the OD values were 1.736 鹵0.026, 1.362 鹵0.013, 0.748 鹵0.024 and 0.326 鹵0.020, respectively. The difference was statistically significant (P 0.05). The expression of PPAR- 緯 gene in gastric cancer SGC-7901 cells was up-regulated with the increase of concentration, and the dose was low. The relative expression of medium dose, high dose gastric compound plasma was 41.1172 鹵1.9615 times of blank plasma, 4448.5509 鹵4.7522 times of blank plasma respectively. It was 14893.2846 鹵1.0381fold, which was significantly different from that of the blank group (P 0.050.Conclusion 1). With the increase of drug concentration and the prolongation of the time of action, the inhibition of SGC-7901 cell proliferation was gradually increased. The results indicated that gastric compound had inhibitory effect on gastric cancer proliferation, and the expression of PPAR 緯 in SGC-7901 cells was increased in a dose-dependent manner after plasma intervention. The results suggest that the plasma containing medicine may inhibit the proliferation of gastric cancer SGC-7901 cells by upregulating the expression of PPAR 緯 gene.
【學(xué)位授予單位】：湖南中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R285

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 周曉霞;王智彪;;曲格列酮上調(diào)PPAR-γ抑制宮頸癌HeLa細(xì)胞ICAM-1和MMP-9表達(dá)[J];南方醫(yī)科大學(xué)學(xué)報(bào);2014年11期

2 汪兵;張義勝;;進(jìn)展期胃癌的分子靶向治療[J];中華臨床醫(yī)師雜志(電子版);2014年22期

3 巴一;;胃癌輔助治療現(xiàn)狀和進(jìn)展[J];中國腫瘤臨床;2013年15期

4 孫海兵;魏永長;涂宏蕾;杜寧;趙陽;胡麗娟;任宏;;COX-2、PKC-α和miR-101在胃癌中的表達(dá)及相關(guān)性[J];南方醫(yī)科大學(xué)學(xué)報(bào);2013年04期

5 李東芳;王云啟;周珉;李陽;吳鴻;;中西醫(yī)結(jié)合治療中晚期胃癌的臨床觀察[J];四川中醫(yī);2012年11期

6 李強(qiáng);黨誠學(xué);;PPARγ mRNA在胃癌組織中的表達(dá)及其與胃癌預(yù)后的關(guān)系[J];實(shí)用癌癥雜志;2012年01期

7 李強(qiáng);黨誠學(xué);;胃癌組織中PPARγ的表達(dá)[J];山東醫(yī)藥;2011年34期

8 廖文秋;張t ;李國慶;;羅格列酮逆轉(zhuǎn)人胃癌y|鼠移植瘤對絲裂霉素耐藥的作用[J];中南醫(yī)學(xué)科學(xué)雜志;2011年01期

9 王麗萍;李洪亮;劉愛東;陸江陽;王宏偉;;PPARγ和MMP-9在胃癌中的表達(dá)及臨床意義[J];山東醫(yī)藥;2010年32期

10 ;Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B[J];癌癥;2010年08期

，

本文編號(hào)：1357822